Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Pneumagen Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. The busiest examiner for this portfolio is ZEMAN, ROBERT A, who is handling 1 busiest examiner pending office action.
With 1 pending office action and 1 distinct examiner, the prosecution process is centralized. The practitioner interacts with ZEMAN, ROBERT A for the 1 busiest examiner pending office action. The 1 distinct art unit indicates that the technical subject matter is being evaluated within a single specialized group at the patent office.
The concentration of the 1 pending office action under 1 distinct examiner allows for a targeted prosecution approach. The practitioner does not need to coordinate between multiple examiners or art units for this portfolio. The Biotechnology & Pharmaceuticals technology area designation and the 1 distinct art unit provide the technical context.
The outcome of the current filings depends on the evaluation by the assigned examiner. Practitioners should prioritize the specific art unit protocols relevant to the subject matter. This arrangement supports a prosecution strategy based on direct engagement with the examiner stated concerns.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZEMAN, ROBERT A | 1 | 54.2% | +27.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17929862 | MODIFIED PROTEIN | ZEMAN, ROBERT A | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17929862 | MODIFIED PROTEIN | ZEMAN, ROBERT A | 1645 | §112Other | Non-Final OA | — | Pending | Sep 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPneumagen Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Robert A Zeman has the most, with 1 of Pneumagen Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
